TLR8 and head and neck squamous cell carcinoma: The small TLR8 agonist motolimod (VTX-2337) exhibits antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) by stimulating natural killer cells and enhancing antibody-dependent cell-mediated toxicity.